Current Opinion on Usage of L-Carnitine in End-Stage Renal Disease Patients on Peritoneal Dialysis
The advantages of peritoneal dialysis (PD) over hemodialysis (HD) are well-documented. Notwithstanding, only a small proportion of patients with end-stage renal disease (ESRD) are managed with PD. This may be related to the high glucose load that PD solutions in current use have on the patient. The...
Main Authors: | Mario Bonomini, Lorenzo Di Liberato, Victor Zammit, Arduino Arduini |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/24/19/3449 |
Similar Items
-
A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience
by: Carmela Rago, et al.
Published: (2021-02-01) -
Proteomic Research in Peritoneal Dialysis
by: Mario Bonomini, et al.
Published: (2020-07-01) -
Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on Peritoneal Dialysis
by: Satoshi Shimizu, et al.
Published: (2019-11-01) -
A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with L-Carnitine Improves Biocompatibility on Human Mesothelial Cells
by: Francesca Piccapane, et al.
Published: (2021-12-01) -
THE PERITONEAL DIALYSIS TREATMENT IN DIALYSIS CENTRE NOVO MESTO
by: Mateja Globokar, et al.
Published: (2004-12-01)